micro-community-banner
 
  • Saved

3yr
Type 2 Diabetes

Over 34 million1 Americans have diabetes, and 90-95%2 of them have Type 2 Diabetes. When diet and lifestyle changes fail to improve glycemic control, metformin3 is typically the first treatment prescribed. Several novel drugs and classes have emerged to treat Type 2 Diabetes after or in addition to metformin. These include GLP-1 receptor agonists, DPP-4 and SGLT2 inhibitors.




  • What factors do you consider when adding to or switching from metformin?

  • What have been your experiences with some of the newer/novel Type 2 Diabetes drugs and classes?



 



References:




  1. National Diabetes Statistics Report, 2020

  2. CDC Diabetes Basics, accessed 11 Jan 2022

  3. Mayo Clinic Type 2 Diabetes Diagnosis and Treatment, accessed 11 Jan 2022


  • 3yr
    Incretin therapy is key as there is a relative deficiency or decreased responsiveness in metabolic syndrome and type 2 DM. With the GIP moiety being added to the GLP-1 Show More
  • 3yr
    Rybelsus ( it is oral Ozempic Semaglutide ) has come up as a block buster diabetic medicine in both managing diabetes and Obeisty , having phenomenal results that Show More

Show More Comments

  • Saved

3yr
Type 2 Diabetes

Over 34 million1 Americans have diabetes, and 90-95%2 of them have Type 2 Diabetes. When diet and lifestyle changes fail to improve glycemic control, metformin3 is typically the first treatment prescribed. Several novel drugs and classes have emerged to treat Type 2 Diabetes after or in addition to metformin. These include GLP-1 receptor agonists, DPP-4 and SGLT2 inhibitors.




  • What factors do you consider when adding to or switching from metformin?

  • What have been your experiences with some of the newer/novel Type 2 Diabetes drugs and classes?



 



References:




  1. National Diabetes Statistics Report, 2020

  2. CDC Diabetes Basics, accessed 11 Jan 2022

  3. Mayo Clinic Type 2 Diabetes Diagnosis and Treatment, accessed 11 Jan 2022


  • 3yr
    Incretin therapy is key as there is a relative deficiency or decreased responsiveness in metabolic syndrome and type 2 DM. With the GIP moiety being added to the GLP-1 Show More
  • 3yr
    Rybelsus ( it is oral Ozempic Semaglutide ) has come up as a block buster diabetic medicine in both managing diabetes and Obeisty , having phenomenal results that Show More

Show More Comments

  • Saved

3yr
Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme - PubMed

Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/35373893/

doi: 10.1111/dom.14710. Online ahead of print. 1 Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 2 Novo Nordisk A/S, Søborg, Denmark. 3 Diabetes Centre, Institute for Clinical and...


Conclusions: Oral semaglutide demonstrated consistently greater HbA1c and body weight reductions across a range of patient characteristics, with greater HbA1c reductions seen at higher baseline HbA1c levels.

  • Saved

3yr
Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis - PubMed

Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/35355921/

1 Department of Endocrinology, Center for Endocrinology, Diabetes, Arthritis and Rheumatism (CEDAR) Superspeciality Healthcare, Dwarka, New Delhi, India. 2 Department of Endocrinology, Manipal Hospitals, Kalpavriksh Healthcare, Dwarka, Gujarat, India. 3...



Conclusion: Tirzepatide has impressive glycemic efficacy and weight-loss data over 1-year clinical use. The need for higher grade, long-term efficacy, and safety data remains.

  • Saved

3yr
Weight Loss Outcomes With Telemedicine During COVID-19 - PubMed

Weight Loss Outcomes With Telemedicine During COVID-19 - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/35360066/

Patients on anti-obesity medications who were followed for 6 months via video or video plus in-person visits (hybrid) experienced clinically significant weight loss. Median number of AOMs were similar among...



Conclusion:. Patients on anti-obesity medications who were followed for 6 months via video or video plus in-person visits (hybrid) experienced clinically significant weight loss. Median number of AOMs were similar among groups, and the most common AOMs were metformin, semaglutide 1.0 mg, and topiramate. More investigation is required to...